# Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

> **NCT00773344** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 25 (actual)

## Conditions studied

- Solid Tumors
- Breast Cancer

## Interventions

- **DRUG:** Tanespimycin

## Key facts

- **NCT ID:** NCT00773344
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-05
- **Final completion:** 2009-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00773344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00773344, "Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00773344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*